why choose us

Course: SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments

CME Credits: 1.00

Released: 2021-11-18

Two messenger RNA (mRNA)-based vaccines, BNT162b2 and mRNA-1273, are currently available for SARS-CoV-2. Both vaccines have been shown to induce protective immunity against SARS-CoV-2 for most healthy individuals. Recent studies have demonstrated a substantially lower rate of antibody induction by both SARS-CoV-2 mRNA vaccines among patients with immunosuppression, including individuals with cancer.- However, the immunogenicity of SARS-CoV-2 mRNA vaccines among patients with selective B-cell deficiency is not well known.


Educational Objective
To identify the key insights or developments described in this article


View Full Course